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Abstract
Background: The characterization of the ABO blood group status is vital for blood transfusion and solid organ
transplantation. Several methods for the molecular characterization of the ABO gene, which encodes the alleles that
give rise to the different ABO blood groups, have been described. However, the application of those methods has
so far been restricted to selected samples and not been applied to population-scale analysis.
Results: We describe a cost-effective method for high-throughput genotyping of the ABO system by next
generation sequencing. Sample specific barcodes and sequencing adaptors are introduced during PCR, rendering
the products suitable for direct sequencing on Illumina MiSeq or HiSeq instruments. Complete sequence coverage
of exons 6 and 7 enables molecular discrimination of the ABO subgroups and many alleles. The workflow was
applied to ABO genotype more than a million samples. We report the allele group frequencies calculated on a
subset of more than 110,000 sampled individuals of German origin. Further we discuss the potential of the
workflow for high resolution genotyping taking the observed allele group frequencies into account. Finally,
sequence analysis revealed 287 distinct so far not described alleles of which the most abundant one was identified
in 174 samples.
Conclusions: The described workflow delivers high resolution ABO genotyping at low cost enabling
population-scale molecular ABO characterization.
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Background
ABO is the clinically most relevant blood group system
in transfusion and transplantation medicine [1]. Using
classical serological methods, donor/recipient pairs are
routinely classified phenotypically into four major blood
groups (A, B, O, and AB). Additional phenotypes with
weak expression patterns are recognized and have been
adopted for ABO subgroup classification [2].
To supplement serological typing, several medium- to
high-throughput molecular typing methods have been
developed for the glycosyltransferase encoding ABO
gene on human chromosome 9. These methods rely on
a broad range of techniques such as restriction fragment
length polymorphism (RFLP), sequence-specific primer
(SSP) PCR, single-strand conformation polymorphism
(SSCP) analysis, or DNA microarray hybridization [3–6].
Most molecular typing methods exclusively target exons
6 and 7, which code for the catalytic domain and com-
prise the majority of the coding sequence, and focus on
single-nucleotide polymorphisms within these two
exons.
While these methods generally suffice for clinical applica-
tions [7], they do not easily scale to the requirements of
routine upfront ABO genotyping of large cohorts of blood
donors [4]. Moreover, the currently most commonly used
molecular typing methods are restricted to detecting the
specific set of alleles included in the assay. Novel alleles are
unlikely to be detected. To date, 367 ABO alleles are
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reported in the Blood Group Antigen Gene Mutation Data-
base (BGMUT, http://www.ncbi.nlm.nih.gov/projects/gv/
rbc). 95 alleles have been added to BGMUT since the data-
base was last described in an academic publication four
years ago [8]. As this trend is not likely to slow down in the
short term, DNA sequencing of the entire exonic sequences
should be employed for more accurate genotyping results.
Several studies have discussed the application of next gen-
eration sequencing (NGS) for ABO blood group genotyping
or demonstrated its potential [9–12]. However, so far it has
not been applied at population-scale to determine ABO
allele frequencies.
Our lab has been applying NGS for high-throughput
HLA genotyping based on direct sequencing of amplicons
on the Illumina MiSeq and HiSeq platforms since begin-
ning of 2013 [13]. We are providing this service to stem
cell donor centers, mainly DKMS German Bone Marrow
Donor Center and affiliated centers, to characterize newly
registered potential stem cell donors. More than 2.5 mil-
lion volunteers have been typed using our NGS approach
since 2013. The implementation of the NGS-based work-
flow for HLA genotyping has reduced costs by more than
50 % as compared to Sanger-based genotyping. Further-
more, this type of workflow allows adding additional genes
of interest to the donor genotyping profile at a minimal
surcharge. Since donor-patient matching of the ABO sta-
tus simplifies transplantation-related patient treatment
procedures and may even improve outcome [14], we
chose to extend the existing NGS-based HLA genotyping
workflow to additionally provide ABO genotyping. Cur-
rently, the major bone marrow donor registries accept
ABO data only at the blood group resolution level (A, B,
AB, O). Therefore, we designed the assay to provide ABO
blood group resolution at minimal costs. This resulted in
the selection of exons 6 and 7 for sequencing, which,
based on the currently known alleles, enable unambiguous
determination of the ABO blood group status. Meanwhile
we have typed 1.69 million samples using this approach.
Here, we describe the workflow and analyze the level
of resolution beyond the blood group level that may be
obtained by an exon 6 and 7 restricted approach: 99.9 %
of the samples can be resolved at the ABO allele or allele
group level. We analyze a subset of 113,367 samples of
German descent to report ABO genotype frequencies at
the resolution level of allele groups. Furthermore, our
workflow readily identifies so far unknown alleles and




We describe a high-throughput workflow for ABO
genotyping based on direct PCR amplicon sequencing
on Illumina MiSeq or HiSeq instruments as described
for HLA typing in Lange et al. [13]. The main advan-
tages of this workflow are simplicity and cost effective-
ness. Hundreds of samples may be pooled immediately
after the PCR reaction as the samples are tagged during
PCR with a molecular barcode that is read during se-
quencing. This approach significantly reduces costs and
hands-on time for all post-PCR processing steps. In
addition, since adapters are incorporated during the
PCR, only four straightforward steps are required to
initiate sequencing: PCR cleanup, quantification, de-
naturation and dilution.
Amplicon length is restricted to the combined forward
and reverse sequencing read length, currently 600 (MiSeq)
or 500 (HiSeq) bases. We designed two assays targeting
exons 6 and 7 of the ABO gene (Fig. 1, Additional file 1:
Table S1). Since the length of exon 7 (686 to 692 bp) ex-
ceeds the amplicon size limit of our approach, ABO assay 1
includes two overlapping PCR reactions to cover exon 7
and one PCR reaction targeting exon 6 (Fig. 1). This de-
livers high resolution but prevents multiplexing the PCR in
one reaction. ABO assay 2 is set up as multiplex PCR reac-
tion covering exon 6 and the central 507 bases of exon 7
(Fig. 1). The multiplexed ABO assay 2 was developed to
simplify the automated hitpicking setup.
The workflow has been applied routinely as part of the
stem cell donor typing program since April 2014. As of
March 2016, a total of 1.69 million samples have been
successfully ABO genotyped. ABO assay 1 PCR is per-
formed alongside assays for HLA, Rh, CCR5Δ32 and
KIR genotyping using 48.48 or 192.24 Fluidigm Access
Array chips or 384-well PCR plates. In addition, ABO
assay 2 is applied on 384-well PCR plates to confirm
Fig. 1 Primer locations for the ABO gene exons 6 and 7. Primers for ABO assay 1 are marked red. Primers for ABO assay 2 are identical to assay 1
in exon 6 and marked blue in exon 7
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results that do not meet the internal quality criteria or
failed in the first round.
In our setting sequencing yields on average more than
1000 reads per amplicon and sample. These reads are
matched to the alleles as listed in the BGMUT database
[8] by our NGS genotyping software neXtype [13]. In con-
trast to many other molecular approaches our sequencing
assays are not limited to detect a subset of the more fre-
quent alleles but may rather detect the full spectrum of
frequent and rare alleles as well as so far undescribed vari-
ants. Our restricted focus on exons 6 and 7, however,
limits the obtainable resolution to alleles that differ in
those exons. Seven alleles lacking exon 6 and 7 sequence
information, four alleles lacking the major part of exon 7
sequence information, 19 alleles lacking phenotype infor-
mation, and one allele of uncertain phenotype were ex-
cluded (Additional file 1: Table S2) reducing the data basis
to 108 A, 68 B and 73 O alleles.
In contrast to Sanger sequencing, NGS delivers phased
information: Every read carries information about the phas-
ing between two or more heterozygous positions. However,
in a short amplicon sequencing workflow, phasing informa-
tion between the individual amplicons is lacking. Often
there is only one possibility for joining amplicons that re-
sults in valid sequence combinations of e.g. exon 6 and 7.
Sometimes, however, both sequences of one exon can be
joined with both sequences of the other exon. In such
cases, the true sequences or alleles cannot be determined
without additional information. For instance, analysis of all
ABO alleles and their sequences showed that samples with
the genotype ABO*O.02.01/ABO*B1.01.01 cannot be distin-
guished from the genotype ABO*O.02.14/ABO*Ax.02.01
due to the lack of phasing information between exons 6
and 7 (Fig. 2). Given the high abundance of the
ABO*O.02.01 and ABO*B1.01.01 alleles and the low likeli-
hood of a genotype combining the two rare alleles
ABO*O.02.14 and ABO*Ax.02.01, we decided to disregard
the possibility of an ABO*O.02.14/ABO*Ax.02.01 combin-
ation. Likewise the genotype A1.01.02/O.02.14 is neglected
in favor of the more likely B1.01.01/O.02.02 allele
combination. However, those rare alleles are unquestion-
ably identified in all other genotypes.
Validation
We validated our workflow by genotyping 468 samples
with known serological blood group status. For 15 sam-
ples (3.2 %) typing failed, either because read counts in
one of the amplicons were too low (8 samples), or be-
cause the allele groups identified in the 3 amplicons did
not intersect and could therefore not be resolved unam-
biguously (7 samples).
451 (99.6 %) of the 453 successfully typed samples were
concordant with the serological status. For 2 samples
(0.4 %) genotyping results (AO) deviated from the sero-
logical status (O). Independent serological testing of fresh
samples confirmed the O-type status for both individuals.
On the other hand, the AO genotype obtained by sequen-
cing was confirmed by an SSP assay. These conflicting re-
sults may partly be explained by the identified alleles:
ABO*Ax.13.01.1 (sample 324) is expected to give rise to a
very weak A phenotype [1, 15]. In accordance with that,
the serum assay failed to detect anti-A2 antibodies at
room temperature. The serological status for the other
sample (226), however, did not show any abnormalities.
The molecular genotype group includes several weak A al-
leles (ABO*Ael.04.01.1, ABO*Aw.13.01.1, ABO*Aw.15.01.1
and ABO*Ax.15.01.1) whose presence could explain the
discrepant findings. Those alleles cannot be excluded by
our approach as they differ from ABO*A1.01 only in in-
tron 6 (ABO*Ael.04.01.1, ABO*Aw.15.01.1), in exon 1
(ABO*Aw.13.01.1) or in our primer binding site covering
20 positions in the 5’ region of exon 7 (ABO*Ax.15.01.1).
This demonstrates the limitations of an exon 6/7 re-
stricted genotyping assay. Such a restricted assay can
therefore currently not replace serological analysis. It
does serve, though, as a cost effective extension that
adds detailed allelic information. Conceptually, an
addition of the missing exons (and introns) is straight-
forward. Within the scope of our approach, however, the
Fig. 2 Phasing issues: Due to lack of phasing information between exons 6 and 7, the genotype ABO*O.02.01/ABO*B1.01.01 cannot be
distinguished from the genotype ABO*O.02.14/ABO*Ax.02.01. For exon 6, sequence 1 may be explained by the alleles ABO*O.02.01 or ABO*O.02.14
(among others). The allele ABO*O.02.01 is composed of exon 6 sequence 1 and exon 7 sequence 1. The allele ABO*O.02.14 is composed of exon 6
sequence 1 and exon 7 sequence 2. Therefore, depending on the phasing between the exonic sequences, different typing results are possible:
the rare Swedish A allele ABO*Ax.02.01 (black) in combination with an O allele (ABO*O.02.14) of unknown frequency (red) or the common B allele
ABO*B1.01.01 and common O allele ABO*O.02.01 (both green)
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ABO genotypes are supposed to serve as additional se-
lection criteria within the search for HLA-matched un-
related hematopoietic stem cell donors. Furthermore,
the ABO status provided by our screening approach has
to be confirmed by standard methods during donor
clearing before stem cell transplantation. Against this
background, a deviation rate of 0.5 % from the sero-
logical status seems acceptable to us.
ABO allele frequencies
The primary purpose of this project was to supple-
ment HLA genotyping with basic ABO blood group
information at low cost. However, the data generated
lends itself to an allele-level frequency analysis. We
chose to analyze a subset of 113,367 samples from in-
dividuals of German descent processed from June
2014 to September 2014. Low DNA concentration
was identified as main source of error when working
with PCR volumes in the sub-microliter range [16].
Therefore, the data set was restricted to samples with
a DNA concentration of higher than 20 ng/μl in
order to minimize the risk for wrong assignments
which could distort the frequency calculations par-
ticularly of low frequency alleles.
As discussed above, two conceptual limitations inter-
fere with full allele-level resolution for every sample:
limited sequence coverage and missing phasing informa-
tion. Despite the limited sequence coverage most ob-
served alleles can be resolved to the third field (e.g.
A1.02.01). However, three A, one B and five O genotypes
include alleles spanning several subtypes (e.g. A1 and
Aw, O.02 and O.67) (see Table 1 for the allele groups
with ambiguities observed in the data set and Additional
file 1: Table S3 for an exhaustive list of allele groups with
ambiguities). Based on the remarks on the abundance of
alleles and allele groups in “The Blood Group Antigen
FactsBook” [17] we assume that most of those alterna-
tive alleles occur at low frequencies in the German
population. However, given the large sample size, some
of those alternative alleles may be present in the data
set. This may result in a slight overestimation of the
more abundant subgroups (e.g. A1, A2, B1) and an
underestimation of the less frequent subgroups (e.g. Ax,
Aw, Bw).
Depending on the alleles present in a particular sam-
ple, the missing phase information may create an add-
itional level of ambiguity for genotyping. However, when
analyzing a large data set retrospectively, a Bayesian
probabilistic framework allows to partially account for
the uncertainty in the data. In short, the algorithm takes
advantage of the fact that the frequencies can be deter-
mined for many samples without phasing problem.
Based on the frequencies for problem-free samples, the
frequencies for the samples with phasing problems are
estimated. In addition, we obtain an estimate of the level
of uncertainty for each frequency estimate.
When applied to our data set of 113,367 genotyped
samples this approach delivered frequency estimates for
82 alleles or allele groups (Fig. 3 and Table 2) ranging
from 0.002 % to 32 %. To our knowledge this is the first
estimation of allelic ABO frequencies on such a large
dataset.
High-resolution genotyping
We further explored the possibilities for high-resolution
genotyping based on exon 6 and 7 sequencing. While an
algorithm as discussed in the previous paragraph is lim-
ited to retrospective frequency estimations, these esti-
mates may help distinguishing between alternative allele
combinations based on their relative likelihood. Given
sufficient difference, the less likely allele combination
may be ignored accepting a minor increase in the error
rate. In cases of allele combinations with similar likeli-
hood both allele combinations should be included in the
genotype result reducing the resolution.
We analyzed all observed genotyping results with un-
resolved phasing with regard to their frequencies and
the relative likelihoods of their allele combinations
(Table 3). We identified 24 unique cases with diverse
properties in our data set. The 15 least abundant cases
have a cumulative frequency of 0.11 % and will affect
only very few samples. The six most abundant cases sum
up to a cumulative frequency of 32 %, demonstrating the
prevalence of the issue. Likewise the relative likelihoods
of two possible allele combinations range from close to
1 to several millions. Two cases (case 4 and 11, Table 3)
as discussed above would lead to a different ABO geno-
type (OB1 versus OAx/OA1). Disregarding the OAx/OA1
combination seems warranted without an inadequate
error risk at least for German samples: Even though the
OB1/OA1 ambiguity has only an odds ratio of 6,271,
given the low frequency of that ambiguity this would
theoretically result in one error in 23 million typed sam-
ples. Twelve of the remaining cases are irrelevant for de-
termining the subgroups as the ambiguities affect only
the next field (e.g. A2.01.01* versus A2.06.01, O.01.01
versus O.01.05). In most circumstances those differences
will not be of interest. Two cases remain with a fre-
quency above 0.1 % and an effect on subgroup results:
For case 2 the OAx combination can be safely ignored,
having a relative likelihood of smaller than 1/100,000.
Case 3 remains unpleasant as it combines a high fre-
quency of 4.5 % with a moderately low relative likelihood
of one in 617. In most scenarios an error rate of 1 in
10,000 samples (4.5 % divided by 617) is probably accept-
able. Otherwise in 4.5 % of the samples OA2 versus OA1
cannot be resolved. We conclude that the missing phasing
information does not interfere with high-resolution
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genotyping for German samples as for 99.9 % of the
samples phasing could be resolved at least to the sub-
group level if an error rate of 0.01 % (A1 versus A2, case
3) is acceptable.
Novel alleles
An intrinsic advantage of sequencing approaches com-
pared to other molecular methods is the ability to iden-
tify and characterize novel alleles. As of March 2016 we
have genotyped 1,693,287 samples for ABO. We identi-
fied 20,190 samples (1.2 %) with indications for the
presence of a novel allele. As the characterization of
novel alleles was not the primary focus of the project,
we attempted verification by replicate sequencing only
for a subset of 4,375 samples (21.7 %). That subset was
not systematically selected over the time course of the
project. It rather reflects historic changes in analysis pol-
icies and automation capacities. For 815 samples
(18.6 %) the replicate sequencing confirmed the presence
of a novel allele with the identical so far unreported se-
quence. A total of 287 unique novel allelic sequences
were found (Additional file 1: Table S4). While 193 of
Table 1 Definition of allele groups spanning multiple ABO subgroups that cannot be resolved based on exons 6 and 7 and their
constituent alleles
Allele group identifier Allele Blood group Subgroup Germana Caucasiana Frequency StDev
A1.01.01* ABO*A1.01.01 A A1 Common Common 20.286 % 0.243 %
ABO*A1.09.01.1 A A1 Undefined Undefined
ABO*Ael.04.01.1 A Ael Unknown Unknown
ABO*Aw.13.01.1 A Aw Unknown Present
ABO*Aw.15.01.1 A Aw Unknown Unknown
ABO*Aw.29.01.1 A Aw Unknown Present
ABO*Ax.15.01.1 A Ax Unknown Unknown
O.02.01* ABO*O.02.01 O O2 Many Many 18.479 % 0.222 %
ABO*O.02.17.1 O O2 Undefined Undefined
ABO*O.67.01 O O67 Undefined Undefined
B1.01.01* ABO*B1.01.01 B B1 Common Common 8.420 % 0.113 %
ABO*Bw.new B Bw Undefined Undefined
A2.01.01* ABO*A2.01.01 A A2 Common Common 6.588 % 0.088 %
ABO*A2.01.02.1 A A2 Common Common
ABO*A2.16.01.1 A A2 Unknown Unknown
ABO*Aw.09.01.1 A Aw Unknown Unknown
ABO*Aw.16.01.1 A Aw Unknown Unknown
ABO*Aw.17.01.1 A Aw Unknown Present
ABO*Aw.22.01.1 A Aw Unknown Unknown
ABO*Aw.27.01.1 A Aw Unknown Unknown
O.02.15* ABO*O.02.15.1 O O2 Undefined Undefined 1.610 % 0.032 %
ABO*O.02.18.1 O O2 Undefined Undefined
O.02.02* ABO*O.02.02 O O2 Unknown Unknown 0.137 % 0.008 %
ABO*O.02.20.1 O O2 Undefined Undefined
ABO*O.54.01.1 O O54 Undefined Undefined
A2.12.01* ABO*A2.09.01.1 A A2 Unknown Unknown 0.043 % 0.004 %
ABO*A2.12.01.1 A A2 Unknown Unknown
ABO*Aw.26.01.1 A Aw Unknown Unknown
O.01.11* ABO*O.01.11.1 O O1 Undefined Undefined 0.014 % 0.003 %
ABO*O.06.01.1 O O6 Unknown Rare
O.02.07* ABO*O.02.07.1 O O2 Undefined Undefined 0.008 % 0.002 %
ABO*O.40.01.1 O O40 Undefined Undefined
aAllele frequency classifications after [15]
*Allele groups as defined here are marked by an asterisk throughout the text
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these sequences were encountered only once, the ten
most common sequences were identified in 369 different
samples. The most abundant sequence was identified in
174 samples correlating to a frequency of 0.01 % in our
data set. Based on the confirmation rate of 18.6 % for
the reanalyzed samples, we estimate that about 3,761 of
the 20,190 originally flagged samples contain novel al-
leles. That would correlate to an overall frequency of
novel alleles of 0.22 %. To exclude the unlikely possibil-
ity of systematic errors due to the applied technology we
analyzed a random selection of 37 samples representing
26 unique novel allelic sequences a third time by PacBio
sequencing (Additional file 1: Table S4), an orthogonal
technology with completely different error profile. All
PacBio resequencing results confirmed the original find-
ings. This study demonstrates the potential of our work-
flow for the detection of novel alleles. To submit the
identified novel sequences to the BGMUT database
more work is required. In particular an approach that
covers the whole gene and provides fully phased se-
quence information should be applied. Based on our ex-
perience with the submission of fully phased HLA genes
we intend to embark on this task soon.
Discussion
Here, we propose a cost-effective workflow for high-
throughput ABO genotyping. Despite the restricted
coverage of exons 6 and 7, the approach delivers allelic
or allele group level resolution for 99.9 % of the samples.
While the frequency analysis based on 113,367 samples
from individuals of German descent allowed us to
propose ways to handle ambiguities originating from un-
resolved phasing, we lack such detailed frequency infor-
mation for the alleles compromising the not resolvable
allele groups (Table 1) whose sequences differ only in
the regions not covered by our approach. Therefore we
cannot judge if those alleles prevent ABO subgroup-level
resolution since they may appear too frequent to disre-
gard them. This limitation is however shared with many
published molecular approaches that a priori limit the
data basis to the more frequent alleles that are readily
distinguishable. Our workflow, however, lends itself to
extend the targeted region to the other exons. Such an
extended workflow could deliver true allelic level ABO
genotyping and resolve the frequencies of the less com-
mon alleles in the so far unresolved allele groups. Even
such an extended workflow would still be very cost-
effective. Main cost factors of our workflow, when
applied at high throughput, are DNA isolation, PCR re-
actions (including target-specific and barcoding primer
oligonucleotides) and sequencing. Costs for DNA isola-
tion and PCR reactions depend largely on the chosen re-
agent providers. Current reagent costs for sequencing on
an Illumina MiSeq (2x300 bp) are well below 1 € per
20,000 reads which would deliver more than plenty of
reads to cover the whole ABO gene. This assumes, how-
ever, that ABO genotyping is performed together with
other targets and/or that the throughput is sufficiently
Fig. 3 Bayesian ABO allele and allele group frequency estimates for 113,367 German samples. Error bars denote standard deviations around the
posterior mean based on 10,000 MCMC iterations. Blood group phenotypes are color-coded in blue (A), red (B) and purple (O). The constituent
alleles combined under allele group identifiers are provided in Table 1. Allele group identifiers ending with an asterisk combine alleles
across subgroups
Lang et al. BMC Genomics  (2016) 17:374 Page 6 of 11
high to utilize the full capacity of the instrument. In our
setup, ABO genotyping is performed alongside of geno-
typing of six HLA loci, CCR5Δ32, KIR and the Rh blood
group. Up to 4,800 samples are jointly analyzed on one
rapid-run flow-cell on HiSeq 2500 instruments resulting
in 60,000 reads per sample on average, at sequencing
reagent costs of about 1 €. This underscores the cost
effectiveness of the described workflow. Given the low
sequencing costs, applying these strategies to an ex-
tended blood group panel seems feasible. The major
challenge would lie in developing highly multiplexed ef-
ficient PCR assays targeting the genes of interest.
While the workflow is slim compared to other sequen-
cing approaches, the sequencing alone runs for two full
days. Taken together, genotyping results can be obtained
within four days. However, in a high-throughput opti-
mized setting the turn-around-time would probably ex-
tend to two or three weeks.
Conclusions
The application of next generation sequencing to blood
group genotyping has been proposed [9, 10] and the feasi-
bility demonstrated in proof-of-concept studies [18–20].
We report the application of NGS to ABO analysis and suc-
cessfully genotyped more than 1.5 million samples. Despite
the restricted focus on exons 6 and 7 the data enabled us to
report frequency data on 82 distinguished alleles or allele
groups. For most of the less abundant alleles this consti-
tutes the first quantitative frequency estimation. While this
approach can by no means substitute serological ABO sta-
tus analysis, it could serve as a cost-effective complementa-
tion to reveal the molecular ABO genotype.
Methods
Samples, DNA isolation and quantification
Samples were provided by DKMS German Bone Marrow
Donor Center and other donor centers for HLA and blood
group typing between April 2014 and December 2015.
DNA was isolated from 150 μl whole blood or a single buc-
cal swab using the magnetic-bead-based “chemagic DNA
Blood Kit special” or “chemagic DNA Buccal Swab kit spe-
cial” (Perkin Elmer, Baesweiler, Germany), respectively.
DNA was eluted in 100 μl elution buffer (10 mM Tris-HCl
pH8.0). DNA concentrations were measured by fluorescence
(SYBR Green, Biozym, Hessisch Oldendorf, Germany) using
the TECAN infinite 200Pro (Tecan, Männedorf,
Table 2 Population-wide frequency estimates for blood groups,
subgroups and allele groups
A 29.482 % B 9.570 % O 60.948 %
A1 20.638 % B1 9.369 % O1 36.619 %
A1.01.01* 20.286 % B1.01.01* 8.420 % O.01.01 31.772 %
A1.01.02 0.023 % B1.01.02 0.008 % O.01.04 0.029 %
A1.02.01 0.101 % B1.01.03 0.007 % O.01.05 0.033 %
A1.02.03 0.228 % B1.01.05 0.924 % O.01.06 0.017 %
A2 6.869 % B1.09.01 0.010 % O.01.07 0.005 %
A2.01.01* 6.588 % Ba 0.089 % O.01.08 4.453 %
A2.02.01 0.004 % Ba.01.02 0.035 % O.01.09 0.006 %
A2.06.01 0.204 % Ba.04.01 0.044 % O.01.10 0.006 %
A2.12.01* 0.043 % Ba.05.01 0.010 % O.01.11* 0.014 %
A2.17.01 0.005 % Bel 0.010 % O.01.13 0.246 %
A2.19.01 0.012 % Bel.01.01 0.010 % O.01.14 0.033 %
A2.20.01 0.013 % Bw 0.103 % O.01.16 0.004 %
A3 0.462 % Bw.04.01 0.010 % O2 22.079 %
A3.02.01 0.454 % Bw.12.01 0.010 % O.02.01* 18.479 %
A3.05.01 0.004 % Bw.14.01 0.057 % O.02.02* 0.137 %
A3.07.01 0.004 % Bw.21.01 0.010 % O.02.04 1.689 %
Ael 0.023 % Bw.25.01 0.017 % O.02.05 0.008 %
Ael.01.01 0.003 % O.02.06 0.023 %
Ael.03.01 0.002 % O.02.07* 0.008 %
Ael.05.01 0.013 % O.02.08 0.011 %
Ael.06.01 0.005 % O.02.10 0.004 %
Aw 0.391 % O.02.13 0.091 %
Aw.01.01 0.004 % O.02.14 0.008 %
Aw.04.01 0.004 % O.02.15* 1.610 %
Aw.05.01 0.003 % O.02.16 0.006 %
Aw.06.01 0.005 % O.02.19 0.004 %
Aw.07.01 0.351 % O3 1.597 %
Aw.10.01 0.005 % O.03.01 1.597 %
Aw.11.01 0.003 % O48 0.149 %
Aw.19.01 0.013 % O.48.01 0.149 %
Aw.25.01 0.005 % O49 0.180 %
Ax 1.099 % O.49.01 0.180 %
Ax.01.01 0.101 % O50 0.139 %
Ax.01.02 0.961 % O.50.01 0.139 %
Ax.02.01 0.006 % O52 0.012 %
Ax.02.02 0.015 % O.52.01 0.012 %
Ax.12.01 0.010 % O53 0.003 %
Ax.13.01 0.004 % O.53.01 0.003 %
Ax.14.01 0.003 % O9 0.171 %
Table 2 Population-wide frequency estimates for blood groups,




*Allele groups as defined here are marked by an asterisk throughout the text
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Switzerland) plate reader. Samples with concentrations of
less than 2 ng/μl were excluded from ABO typing.
PCR amplification
PCR amplification was performed using 48.48 or 192.24
Fluidigm Access Array IFCs (Fluidigm Corporation,
South San Francisco, USA) in combination with the
Roche High Fidelity Fast Start Kit (Roche, Basel,
Switzerland) as previously described [14]. We used a ther-
mal profile of 50 °C for 2 min, 70 °C for 20 min, 95 °C
for 10 min, followed by 20 cycles at 95 °C for 25 s, 60 °C
for 30 s and 72 °C for 90 s and additional 15 cycles at
95 °C for 25 s, 50 °C for 30 s and 72 °C for 90 s and a
finishing step at 72 °C for 5 min. PCR setup included
the target-specific and the barcoding primers.
Alternatively, amplification was performed in 384-well
plates with 2 μl template DNA, 1 μl 10x buffer mix without
MgCl2 (Roche Fast Start Kit), 0.8 μl 25 mM MgCl2, 0.5 μl
DMSO, 0.2 μl 10 mM dNTPs each (Roche Fast Start Kit),
0.1 μl Fast Start Taq Polymerase (5 U/μl) (Roche Fast Start
Kit), 4.4 μl PCR grade water and 1 μl of target-specific pri-
mer mix. We used a thermal profile of 95 °C for 4 min
followed by 35 cycles at 95 °C for 25 s, 57 °C for 30 s and
72 °C for 90 s, and a finishing step at 72 °C for 5 min.
Amplicons belonging to one sample were pooled with an
CyBi-Well Vario system (Analytik Jena AG, Jena, Germany)
and 2 μl transferred to an 9 μl pre-aliquoted PCR master
mix including 1 μl 10x buffer mix without MgCl2 (Roche
Fast Start Kit), 1 μl 25 mM MgCl2, 0.2 μl DMSO, 0.2 μl
10 mM dNTPs each (Roche Fast Start Kit), 0.1 μl Fast Start
Taq Polymerase (5 U/μl) (Roche Fast Start Kit), 3.5 μl PCR
grade water as well as 2 μl of barcode primers (2 μM equi-
molar mix of index 1 and index 2). Barcoding PCR was per-
formed with the following thermal profile: 95 °C for 4 min,
10 cycles at 95 °C for 25 s, 50 °C for 30 s and 72 °C for 90 s,
and a finishing step at 72 °C for 5 min.
We employed two different types of assays (ABO assay
1 and ABO assay 2, compare Fig. 1). For ABO assay 1,
Table 3 Genotypes and their corresponding frequencies where the lack of phasing information leads to alternative outcomes
(Group A or B). The relative likelihood of A vs. B is estimated based on allele frequencies




Frequency Identifier Frequency Identifier Frequency Identifier Frequency Identifier Frequency a/b
1 12.545 % O.01.01 31.772 % O.02.01* 18.479 % O.01.11* 0.014 % O.02.02* 0.137 % 298,326 No
2 8.092 % A1.01.01* 20.286 % O.02.01* 18.479 % Ax.02.02 0.015 % O.02.02* 0.137 % 187,949 Yes
3 4.511 % A2.01.01* 6.588 % O.01.01 31.772 % A1.01.01* 20.286 % O.01.06 0.017 % 617 Yes
4 3.250 % B1.01.01* 8.420 % O.02.01* 18.479 % Ax.02.01 0.006 % O.02.14 0.008 % 3,313,940 Yes
5 2.868 % A1.01.01* 20.286 % A2.01.01* 6.588 % A1.02.01 0.101 % A2.06.01 0.204 % 6,501 No
6 1.095 % O.01.01 31.772 % O.02.15* 1.610 % O.01.14 0.033 % O.02.05 0.008 % 193,859 No
7 0.113 % O.01.01 31.772 % O.09.01 0.163 % O.01.05 0.033 % O.09.03 0.005 % 30,220 No
8 0.071 % A1.02.01 0.101 % O.01.01 31.772 % A1.01.01* 20.286 % O.01.05 0.033 % 5 No
9 0.068 % A1.01.01* 20.286 % O.09.01 0.163 % A1.02.01 0.101 % O.09.03 0.005 % 6,284 No
10 0.027 % A2.01.01* 6.588 % O.01.05 0.033 % A1.02.01 0.101 % O.01.06 0.017 % 128 Yes
11 0.026 % B1.01.01* 8.420 % O.02.02* 0.137 % A1.01.02 0.023 % O.02.14 0.008 % 6,271 Yes
12 0.016 % O.01.01 31.772 % O.02.06 0.023 % O.01.10 0.006 % O.02.02* 0.137 % 853 No
13 0.010 % A1.01.02 0.023 % O.02.01* 18.479 % Ax.02.01 0.006 % O.02.02* 0.137 % 528 Yes
14 0.007 % Ax.02.02 0.015 % O.01.01 31.772 % A1.01.01* 20.286 % O.01.11* 0.014 % 2 Yes
15 0.005 % A1.02.01 0.101 % O.02.15* 1.610 % A2.20.01 0.013 % O.02.05 0.008 % 1,515 Yes
16 0.003 % O.01.10 0.006 % O.02.01* 18.479 % O.01.11* 0.014 % O.02.06 0.023 % 350 No
17 0.002 % A1.01.01* 20.286 % Ax.02.01 0.006 % A1.01.02 0.023 % Ax.02.02 0.015 % 356 No
18 0.002 % A1.01.01* 20.286 % Aw.25.01 0.005 % A1.02.01 0.101 % A3.02.01 0.454 % 2 Yes
19 0.002 % A1.01.01* 20.286 % B1.01.02 0.008 % A1.01.02 0.023 % B1.01.05 0.924 % 8 No
20 0.002 % Aw.25.01 0.005 % O.01.01 31.772 % A3.02.01 0.454 % O.01.05 0.033 % 10 Yes
21 0.001 % A1.01.02 0.023 % A2.01.01* 6.588 % A1.02.03 0.228 % A2.06.01 0.204 % 3 No
22 0.001 % A2.01.01* 6.588 % O.01.11* 0.014 % Ax.02.02 0.015 % O.01.06 0.017 % 389 Yes
23 0.001 % A1.01.01* 20.286 % Aw.01.01 0.004 % A2.06.01 0.204 % A2.17.01 0.005 % 78 Yes
24 0.001 % A2.01.01* 6.588 % O.09.03 0.005 % A2.06.01 0.204 % O.09.01 0.163 % 1 No
*Allele groups as defined here are marked by an asterisk throughout the text
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PCR was performed for three amplicons, exon 6 (192 bp),
exon 7 amplicon a (460 bp) and exon 7 amplicon b
(328 bp). Amplification reactions for exon 6 (0.85 μM
each primer) and exon 7a (0.75 μM each primer) were
multiplexed, amplification for exon 7b (0.5 μM each pri-
mer) was performed separately. For ABO assay 2, only the
central portion of exon 7 (507 bp) was amplified and amp-
lification reactions for exon 6 (0.3 μM each primer) and
exon 7 (0.25 μM each primer) were multiplexed.
Target-specific primers and index primers were obtained
from metabion (metabion international AG, Planegg,
Germany).
Library preparation and sequencing
For sequencing library preparation we pooled 48 barcoded
samples from a 48.48 Access Array, 2 x 96 barcoded sam-
ples from a 192.24 Access Array, or all barcoded amplicons
from one 384-well plate, respectively.
Pooled PCR products were purified with SPRIselect
Beads (BeckmanCoulter, Brea, USA) using a ratio of 0.7:1
beads to PCR product. Purified amplicon pools were
diluted 1:4000 for quantification by qPCR. Pooling, purifi-
cation and subsequent dilution for qPCR quantification
were performed on Biomek 3000 or Biomek NX worksta-
tions (Beckman Coulter, Brea, USA). qPCR was performed
on an ABI-StepOnePlus qPCR cycler (Thermo Fisher,
Carlsbad, USA) using the Library Quant Illumina Kit
(KAPA Biosystems, Boston, USA) with standards in a range
from 0.2 fM to 20 pM.
The purified and quantified amplicon pools were
mixed in equimolar amounts and prepared as recom-
mended by Illumina (MiSeq Reagent Kit v2-Reagent
Preparation Guide). Libraries were loaded at 12.5 to 18.5
pM onto MiSeq or HiSeq flow cells with 10 % PhiX
spiked in. Paired-end sequencing was performed at 249,
251 or 260 (ABO assay 2) cycles.
Confirmatory sequencing of novel ABO alleles was per-
formed using single molecule real-time (SMRT) sequen-
cing on a Pacific Bioscience RS II instrument. ABO genes
spanning exons 3 to 7 were amplified by long-range PCR.
A barcoded sequencing library was prepared using the
SMRTbell Template Prep Kit 1.0 (Part number 100-259-
100) from Pacific Biosciences following standard proto-
cols. Base calling and demultiplexing was performed using
Pacific Biosciences’ SMRT Portal. Sequence reads were
mapped against ABO reference alleles (ABO*A1.01.01.1
for antigens A and O, ABO*B1.01.01.1 for antigen B) with
BWA-MEM [21] using PacBio settings (-x pacbio) and
subsequently visually inspected in IGV [22].
Genotyping
Next generation sequencing based ABO genotyping was
implemented in the genotyping application neXtype
using the same principles as described previously for
HLA allele typing [13]. Briefly, neXtype utilizes a set of
reference allele sequences against which query sequences
are matched for each exon separately. If different alleles
share an exonic sequence, a query sequence will match
multiple target alleles per exon. We refer to these sets of
matched target alleles as Exon Allele Groups (EAGs). A
final ABO genotype assignment for a sample is obtained
by intersecting the member alleles of all EAGs across
exons 6, 7a and 7b. If only one (in a homozygous sam-
ple) or two (in a heterozygous sample) alleles are shared
across EAGs across exons, the sample ABO genotype
can be fully resolved. If multiple alleles share the same
sequences in the amplified region, those alleles cannot
be resolved unambiguously. We distinguish the following
levels of resolution (low to high): blood group (A, B, O),
subgroup (e.g. A1, Ax, B1, O1, O2), allele groups (set of
alleles derived from at least two subgroups), second field
allelic resolution (e.g. A1.01), third field allelic resolution
(e.g. A1.01.02) and full allelic resolution (e.g. A1.01.01.1).
Allele group identifiers and their constituent alleles are
provided in Table 1.
An additional layer of ambiguity arises if, e.g., the two
EAGs at one exon intersect each with two EAGs at an-
other exon. In this case the phase between exons cannot
be resolved and multiple solutions for the underlying
genotype exist.
As a reference for ABO typing by neXtype we used
the 280 ABO alleles currently available from the NCBI
dbRBC Alignment Viewer (http://www.ncbi.nlm.nih.gov/
projects/gv/rbc/align.fcgi?cmd=aligndisplay&user_id=0&
probe_id=0&source_id=0&locus_id=61&locus_group=3&
proto_id=0&kit_id=0&banner=1#). Seven ABO alleles
lacked exon 6/7 sequence information, in four alleles the
major part of exon 7 is unknown, 19 alleles lacked pheno-
type information, and for one allele the phenotype is
uncertain (Additional file 1: Table S2). These alleles were
excluded, reducing our reference allele set to 108 A, 68 B
and 73 O alleles.
Allele group frequency estimation
For ABO allele group frequency estimation a subset of
124,206 donor samples typed between June 2014 and
September 2014 for DKMS German Bone Marrow
Donor Center was extracted from the total data set.
Only samples with a DNA concentration ≥ 20 ng/μl
were included. For each sample, genotyping was per-
formed using neXtype as described above. 123,250 of
the samples could be successfully genotyped. There-
fore, the failure rate for these high quality samples was
below 1 %. Based on self-declared ethnic origin,
113,367 of these donors were of German descent and
therefore included in the final analysis. For 67 % of
these samples (76,276) an unambiguous genotype or
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allele group genotype could be assigned, i.e. there was
no phasing ambiguity across exons (see above). In
33 % of the cases (37,091 samples) multiple genotypes
or allele group genotypes could be mapped to the par-
ticular EAG compositions. Both groups were included
in further analyses.
To estimate allele frequencies, we mapped observed
genotype frequencies for unambiguous genotype assign-
ments to allele frequencies assuming standard Hardy-
Weinberg proportions. For ambiguous genotype assign-
ments, observed frequencies were mapped to the sum of
the individual genotype probabilities that an ambiguous
genotype was composed of. We used these mappings to
formulate a Bayesian model for multinomial frequency
estimation implemented in JAGS (version 3.4.0, http://
mcmc-jags.sourceforge.net) [23]. Additional file 2 (ABO_
model.bug) provides the model specifications in the BUGS
language [24]. Additional file 3 (ABO_count.data) provides
the raw count data for EAG groups in the order in which
they appear in the model. Additional file 4 (AlleleGroup
Identifiers.csv) provides the mapping from EAG group
codes to the allele group identifiers used in this paper. The
mean and standard deviation of allele group frequency
estimates were estimated from the posterior distribution
generated by 10,000 MCMC iterations after a burn-in of
10,000 iterations. All calculations were performed in R




Serological characterization of the blood samples was per-
formed by German Red Cross (DRK) Blood Donor Service
Nord-Ost gGmbH (Institut Chemnitz) and DRK Blood
Donor Service Baden-Württemberg - Hessen, Ulm and
Baden-Baden, Germany.
SSP-PCR
The “RBC-Ready Gene ABO” SSP-PCR-Kit (Inno-Train
Diagnostik GmbH, Kronberg im Taunus, Germany) was
used according to manufacturer’s instructions.
Additional files
Additional file 1: Table S1. Primer sequences for ABO assay 1 and 2.
Table S2. Alleles excluded from the reference allele set downloaded
from NCBI dbRBC. Table S3. Alleles included in our final reference allele
set and definition of allele groups as used in this study. Prevalence
information of alleles are based on “The Blood Group Antigen FactsBook”
[17], and the estimated frequencies are based on 113,367 German
samples. Table S4. Alleles identified with so far undescribed nucleotide
substitutions and structural variations. We provide numbers of observations
per allele and positions of nucleotide changes relative to the cDNA of the
reference alleles (ABO*A1.01.01.1 for antigens A and O, ABO*B1.01.01.1 for
antigen B). A putative antigen designation was derived from sequence
similarities to the exons harboring the nucleotide changes. (XLSX 38 kb)
Additional file 2: JAGS model specification file (ABO_model.bug).
(BUG 38 kb)
Additional file 3: EAG group frequency counts (ABO_count.data) as input
for the JAGS model specified in “ABO_model.bug”. (DATA 879 bytes)
Additional file 4: Mappings from EAG group codes as used in the JAGS
model calculations to the allele groups (AlleleGroupIdentifiers.csv).
(CSV 6 kb)
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